Prednisone

First approved in 1955

Details

Stereochemistry	ABSOLUTE
Molecular Formula	C21H26O5
Molecular Weight	358.4281
Optical Activity	UNSPECIFIED
Defined Stereocenters	6 / 6
E/Z Centers	0
Charge	0

SHOW SMILES / InChI

Structure Search

SMILES

C[C@]12CC(=O)[C@H]3[C@@H](CCC4=CC(=O)C=C[C@]34C)[C@@H]1CC[C@]2(O)C(=O)CO

InChI

InChIKey=XOFYZVNMUHMLCC-ZPOLXVRWSA-N

InChI=1S/C21H26O5/c1-19-7-5-13(23)9-12(19)3-4-14-15-6-8-21(26,17(25)11-22)20(15,2)10-16(24)18(14)19/h5,7,9,14-15,18,22,26H,3-4,6,8,10-11H2,1-2H3/t14-,15-,18+,19-,20-,21-/m0/s1

HIDE SMILES / InChI

Molecular Formula	C21H26O5
Molecular Weight	358.4281
Charge	0
Count

Stereochemistry	ABSOLUTE
Additional Stereochemistry	No
Defined Stereocenters	6 / 6
E/Z Centers	0
Optical Activity	UNSPECIFIED

Description
Sources: https://books.google.ru/books?id=0vXTBwAAQBAJ&pg=PA1012&lpg=PA1012&dq=prednazate+prednisolone&source=bl&ots=6IVjr7YAxt&sig=n3FMmropI-ytuQms6m0VusBrXNc&hl=ru&sa=X&ved=0ahUKEwilpZPbib7PAhXMESwKHZaaB18Q6AEIOzAE#v=onepage&q=prednazate%20prednisolone&f=false Retrieved from Dictionary of drugs: Chemical data, structures and bibliographies, edited by J. Elks and C. R. Ganellin, p.1012http://www.accessdata.fda.gov/drugsatfda_docs/label/2013/202020s003lbl.pdfhttps://www.drugs.com/pro/prednisolone-sodium-phosphate-oral-solution.html | https://humanpara.org/prednisone-and-prednisolone/ | https://www.drugbank.ca/drugs/DB00860http://www.accessdata.fda.gov/drugsatfda_docs/label/2007/017469s040lbl.pdfhttps://medikamio.com/de-de/medikamente/prednisolut-1000-mg/pil
Curator's Comment: description was created based on several sources, including https://www.ncbi.nlm.nih.gov/pubmed/3580023

Prednisolone hemisuccinate is a prodrug of a glucocorticoid agonist prednisolone, which is marketed under trade name Prednisolut in Germany and Austria. Prednisolone hemisuccinate is used in emergency medicine to treate shock due to allergic reaction, insect and snake bites, in neurology to treat brain edema and meningitis, in transplantation medicine to reduce risk of organ refection after kidney transplane, in pneumology to treat acute asthma attack, pulmonary edema, in severe or life-threatening situation in rheumatic diseases.

CNS Activity

Originator

Approval Year

Targets

Primary Target	Pharmacology	Potency
Glucocorticoid receptor 173 Target ID: CHEMBL2034 Sources: https://www.ncbi.nlm.nih.gov/pubmed/25965047 \| https://www.drugbank.ca/drugs/DB00860	Agonist 2752	5.7 nM [EC50]
Glucocorticoid receptor 173 Target ID: CHEMBL2034 Sources: http://www.accessdata.fda.gov/drugsatfda_docs/label/2013/202020s003lbl.pdf	Agonist 2752
Glucocorticoid receptor 173 Target ID: CHEMBL2034 Sources: http://dictionary.sensagent.com/prednisone/en-en/	Agonist 2752
Glucocorticoid receptor 173 Target ID: CHEMBL2034 Sources: https://www.genome.jp/dbget-bin/www_bget?dr:D08413	Agonist 2752
Glucocorticoid receptor 173 Target ID: CHEMBL2034 Sources: http://www.accessdata.fda.gov/drugsatfda_docs/label/2007/017469s040lbl.pdf	Agonist 2752	2.4 nM [Ki]
Glucocorticoid and meneralocorticoid receptor agonists/antagonists 23 Target ID: map07225 Sources: http://www.genome.jp/dbget-bin/www_bget?dr:D02156	Agonist 2752

Conditions

Condition	Modality	Highest Phase	Product
Allergic states 22 Sources: https://www.drugs.com/pro/prednisolone-sodium-phosphate-oral-solution.html	Primary	Approved 8583	Prednisolone Approved Use Prednisolone Sodium Phosphate Oral Solution (10 mg Prednisolone per 5 mL) is indicated in the following conditions: 1. Allergic States Control of severe or incapacitating allergic conditions intractable to adequate trials of conventional treatment in adult and pediatric populations with: seasonal or perennial allergic rhinitis; asthma; contact dermatitis; atopic dermatitis; serum sickness; drug hypersensitivity reactions. 2. Dermatologic Diseases Pemphigus; bullous dermatitis herpetiformis; severe erythema multiforme (Stevens-Johnson syndrome); exfoliative erythroderma; mycosis fungoides. 3. Edematous States To induce diuresis or remission of proteinuria in nephrotic syndrome in adults with lupus erythematosus and in adults and pediatric populations, with idiopathic nephrotic syndrome, without uremia. 4. Endocrine Disorders Primary or secondary adrenocortical insufficiency (hydrocortisone or cortisone is the first choice; synthetic analogs may be used in conjunction with mineralocorticoids where applicable; in infancy mineralocorticoid supplementation is of particular importance); congenital adrenal hyperplasia; hypercalcemia associated with cancer; nonsuppurative thyroiditis. 5. Gastrointestinal Diseases To tide the patient over a critical period of the disease in: ulcerative colitis; regional enteritis. 6. Hematologic Disorders Idiopathic thrombocytopenic purpura in adults; selected cases of secondary thrombocytopenia; acquired (autoimmune) hemolytic anemia; pure red cell aplasia; Diamond-Blackfan anemia. 7. Neoplastic Diseases For the treatment of acute leukemia and aggressive lymphomas in adults and children. 8. Nervous System Acute exacerbations of multiple sclerosis. 9. Ophthalmic Diseases Uveitis and ocular inflammatory conditions unresponsive to topical corticosteroids; temporal arteritis; sympathetic ophthalmia. 10. Respiratory Diseases Symptomatic sarcoidosis; idiopathic eosinophilic pneumonias; fulminating or disseminated pulmonary tuberculosis when used concurrently with appropriate antituberculous chemotherapy; asthma (as distinct from allergic asthma listed above under "Allergic States"), hypersensitivity pneumonitis, idiopathic pulmonary fibrosis, acute exacerbations of chronic obstructive pulmonary disease (COPD), and Pneumocystis carinii pneumonia (PCP) associated with hypoxemia occurring in an HIV (+) individual who is also under treatment with appropriate anti-PCP antibiotics. Studies support the efficacy of systemic corticosteroids for the treatment of these conditions: allergic bronchopulmonary aspergillosis, idiopathic bronchiolitis obliterans with organizing pneumonia. 11. Rheumatic Disorders As adjunctive therapy for short term administration (to tide the patient over an acute episode or exacerbation) in: psoriatic arthritis; rheumatoid arthritis, including juvenile rheumatoid arthritis (selected cases may require low dose maintenance therapy); ankylosing spondylitis; acute and subacute bursitis; acute nonspecific tenosynovitis; acute gouty arthritis; epicondylitis. For the treatment of systemic lupus erythematosus, dermatomyositis (polymyositis), polymyalgia rheumatica, Sjogren's syndrome, relapsing polychondritis, and certain cases of vasculitis. 12. Miscellaneous Tuberculous meningitis with subarachnoid block or impending block, tuberculosis with enlarged mediastinal lymph nodes causing respiratory difficulty, and tuberculosis with pleural or pericardial effusion (appropriate antituberculous chemotherapy must be used concurrently when treating any tuberculosis complications); trichinosis with neurologic or myocardial involvement; acute or chronic solid organ rejection (with or without other agents). Launch Date 1955
Mycosis fungoides 31 Sources: https://www.drugs.com/pro/prednisolone-sodium-phosphate-oral-solution.html	Primary	Approved 8583	Prednisolone Approved Use Prednisolone Sodium Phosphate Oral Solution (10 mg Prednisolone per 5 mL) is indicated in the following conditions: 1. Allergic States Control of severe or incapacitating allergic conditions intractable to adequate trials of conventional treatment in adult and pediatric populations with: seasonal or perennial allergic rhinitis; asthma; contact dermatitis; atopic dermatitis; serum sickness; drug hypersensitivity reactions. 2. Dermatologic Diseases Pemphigus; bullous dermatitis herpetiformis; severe erythema multiforme (Stevens-Johnson syndrome); exfoliative erythroderma; mycosis fungoides. 3. Edematous States To induce diuresis or remission of proteinuria in nephrotic syndrome in adults with lupus erythematosus and in adults and pediatric populations, with idiopathic nephrotic syndrome, without uremia. 4. Endocrine Disorders Primary or secondary adrenocortical insufficiency (hydrocortisone or cortisone is the first choice; synthetic analogs may be used in conjunction with mineralocorticoids where applicable; in infancy mineralocorticoid supplementation is of particular importance); congenital adrenal hyperplasia; hypercalcemia associated with cancer; nonsuppurative thyroiditis. 5. Gastrointestinal Diseases To tide the patient over a critical period of the disease in: ulcerative colitis; regional enteritis. 6. Hematologic Disorders Idiopathic thrombocytopenic purpura in adults; selected cases of secondary thrombocytopenia; acquired (autoimmune) hemolytic anemia; pure red cell aplasia; Diamond-Blackfan anemia. 7. Neoplastic Diseases For the treatment of acute leukemia and aggressive lymphomas in adults and children. 8. Nervous System Acute exacerbations of multiple sclerosis. 9. Ophthalmic Diseases Uveitis and ocular inflammatory conditions unresponsive to topical corticosteroids; temporal arteritis; sympathetic ophthalmia. 10. Respiratory Diseases Symptomatic sarcoidosis; idiopathic eosinophilic pneumonias; fulminating or disseminated pulmonary tuberculosis when used concurrently with appropriate antituberculous chemotherapy; asthma (as distinct from allergic asthma listed above under "Allergic States"), hypersensitivity pneumonitis, idiopathic pulmonary fibrosis, acute exacerbations of chronic obstructive pulmonary disease (COPD), and Pneumocystis carinii pneumonia (PCP) associated with hypoxemia occurring in an HIV (+) individual who is also under treatment with appropriate anti-PCP antibiotics. Studies support the efficacy of systemic corticosteroids for the treatment of these conditions: allergic bronchopulmonary aspergillosis, idiopathic bronchiolitis obliterans with organizing pneumonia. 11. Rheumatic Disorders As adjunctive therapy for short term administration (to tide the patient over an acute episode or exacerbation) in: psoriatic arthritis; rheumatoid arthritis, including juvenile rheumatoid arthritis (selected cases may require low dose maintenance therapy); ankylosing spondylitis; acute and subacute bursitis; acute nonspecific tenosynovitis; acute gouty arthritis; epicondylitis. For the treatment of systemic lupus erythematosus, dermatomyositis (polymyositis), polymyalgia rheumatica, Sjogren's syndrome, relapsing polychondritis, and certain cases of vasculitis. 12. Miscellaneous Tuberculous meningitis with subarachnoid block or impending block, tuberculosis with enlarged mediastinal lymph nodes causing respiratory difficulty, and tuberculosis with pleural or pericardial effusion (appropriate antituberculous chemotherapy must be used concurrently when treating any tuberculosis complications); trichinosis with neurologic or myocardial involvement; acute or chronic solid organ rejection (with or without other agents). Launch Date 1955
Primary or secondary adrenocortical insufficiency 22 Sources: https://www.drugs.com/pro/prednisolone-sodium-phosphate-oral-solution.html	Primary	Approved 8583	Prednisolone Approved Use Prednisolone Sodium Phosphate Oral Solution (10 mg Prednisolone per 5 mL) is indicated in the following conditions: 1. Allergic States Control of severe or incapacitating allergic conditions intractable to adequate trials of conventional treatment in adult and pediatric populations with: seasonal or perennial allergic rhinitis; asthma; contact dermatitis; atopic dermatitis; serum sickness; drug hypersensitivity reactions. 2. Dermatologic Diseases Pemphigus; bullous dermatitis herpetiformis; severe erythema multiforme (Stevens-Johnson syndrome); exfoliative erythroderma; mycosis fungoides. 3. Edematous States To induce diuresis or remission of proteinuria in nephrotic syndrome in adults with lupus erythematosus and in adults and pediatric populations, with idiopathic nephrotic syndrome, without uremia. 4. Endocrine Disorders Primary or secondary adrenocortical insufficiency (hydrocortisone or cortisone is the first choice; synthetic analogs may be used in conjunction with mineralocorticoids where applicable; in infancy mineralocorticoid supplementation is of particular importance); congenital adrenal hyperplasia; hypercalcemia associated with cancer; nonsuppurative thyroiditis. 5. Gastrointestinal Diseases To tide the patient over a critical period of the disease in: ulcerative colitis; regional enteritis. 6. Hematologic Disorders Idiopathic thrombocytopenic purpura in adults; selected cases of secondary thrombocytopenia; acquired (autoimmune) hemolytic anemia; pure red cell aplasia; Diamond-Blackfan anemia. 7. Neoplastic Diseases For the treatment of acute leukemia and aggressive lymphomas in adults and children. 8. Nervous System Acute exacerbations of multiple sclerosis. 9. Ophthalmic Diseases Uveitis and ocular inflammatory conditions unresponsive to topical corticosteroids; temporal arteritis; sympathetic ophthalmia. 10. Respiratory Diseases Symptomatic sarcoidosis; idiopathic eosinophilic pneumonias; fulminating or disseminated pulmonary tuberculosis when used concurrently with appropriate antituberculous chemotherapy; asthma (as distinct from allergic asthma listed above under "Allergic States"), hypersensitivity pneumonitis, idiopathic pulmonary fibrosis, acute exacerbations of chronic obstructive pulmonary disease (COPD), and Pneumocystis carinii pneumonia (PCP) associated with hypoxemia occurring in an HIV (+) individual who is also under treatment with appropriate anti-PCP antibiotics. Studies support the efficacy of systemic corticosteroids for the treatment of these conditions: allergic bronchopulmonary aspergillosis, idiopathic bronchiolitis obliterans with organizing pneumonia. 11. Rheumatic Disorders As adjunctive therapy for short term administration (to tide the patient over an acute episode or exacerbation) in: psoriatic arthritis; rheumatoid arthritis, including juvenile rheumatoid arthritis (selected cases may require low dose maintenance therapy); ankylosing spondylitis; acute and subacute bursitis; acute nonspecific tenosynovitis; acute gouty arthritis; epicondylitis. For the treatment of systemic lupus erythematosus, dermatomyositis (polymyositis), polymyalgia rheumatica, Sjogren's syndrome, relapsing polychondritis, and certain cases of vasculitis. 12. Miscellaneous Tuberculous meningitis with subarachnoid block or impending block, tuberculosis with enlarged mediastinal lymph nodes causing respiratory difficulty, and tuberculosis with pleural or pericardial effusion (appropriate antituberculous chemotherapy must be used concurrently when treating any tuberculosis complications); trichinosis with neurologic or myocardial involvement; acute or chronic solid organ rejection (with or without other agents). Launch Date 1955
Hematologic disorders 22 Sources: https://www.drugs.com/pro/prednisolone-sodium-phosphate-oral-solution.html	Primary	Approved 8583	Prednisolone Approved Use Prednisolone Sodium Phosphate Oral Solution (10 mg Prednisolone per 5 mL) is indicated in the following conditions: 1. Allergic States Control of severe or incapacitating allergic conditions intractable to adequate trials of conventional treatment in adult and pediatric populations with: seasonal or perennial allergic rhinitis; asthma; contact dermatitis; atopic dermatitis; serum sickness; drug hypersensitivity reactions. 2. Dermatologic Diseases Pemphigus; bullous dermatitis herpetiformis; severe erythema multiforme (Stevens-Johnson syndrome); exfoliative erythroderma; mycosis fungoides. 3. Edematous States To induce diuresis or remission of proteinuria in nephrotic syndrome in adults with lupus erythematosus and in adults and pediatric populations, with idiopathic nephrotic syndrome, without uremia. 4. Endocrine Disorders Primary or secondary adrenocortical insufficiency (hydrocortisone or cortisone is the first choice; synthetic analogs may be used in conjunction with mineralocorticoids where applicable; in infancy mineralocorticoid supplementation is of particular importance); congenital adrenal hyperplasia; hypercalcemia associated with cancer; nonsuppurative thyroiditis. 5. Gastrointestinal Diseases To tide the patient over a critical period of the disease in: ulcerative colitis; regional enteritis. 6. Hematologic Disorders Idiopathic thrombocytopenic purpura in adults; selected cases of secondary thrombocytopenia; acquired (autoimmune) hemolytic anemia; pure red cell aplasia; Diamond-Blackfan anemia. 7. Neoplastic Diseases For the treatment of acute leukemia and aggressive lymphomas in adults and children. 8. Nervous System Acute exacerbations of multiple sclerosis. 9. Ophthalmic Diseases Uveitis and ocular inflammatory conditions unresponsive to topical corticosteroids; temporal arteritis; sympathetic ophthalmia. 10. Respiratory Diseases Symptomatic sarcoidosis; idiopathic eosinophilic pneumonias; fulminating or disseminated pulmonary tuberculosis when used concurrently with appropriate antituberculous chemotherapy; asthma (as distinct from allergic asthma listed above under "Allergic States"), hypersensitivity pneumonitis, idiopathic pulmonary fibrosis, acute exacerbations of chronic obstructive pulmonary disease (COPD), and Pneumocystis carinii pneumonia (PCP) associated with hypoxemia occurring in an HIV (+) individual who is also under treatment with appropriate anti-PCP antibiotics. Studies support the efficacy of systemic corticosteroids for the treatment of these conditions: allergic bronchopulmonary aspergillosis, idiopathic bronchiolitis obliterans with organizing pneumonia. 11. Rheumatic Disorders As adjunctive therapy for short term administration (to tide the patient over an acute episode or exacerbation) in: psoriatic arthritis; rheumatoid arthritis, including juvenile rheumatoid arthritis (selected cases may require low dose maintenance therapy); ankylosing spondylitis; acute and subacute bursitis; acute nonspecific tenosynovitis; acute gouty arthritis; epicondylitis. For the treatment of systemic lupus erythematosus, dermatomyositis (polymyositis), polymyalgia rheumatica, Sjogren's syndrome, relapsing polychondritis, and certain cases of vasculitis. 12. Miscellaneous Tuberculous meningitis with subarachnoid block or impending block, tuberculosis with enlarged mediastinal lymph nodes causing respiratory difficulty, and tuberculosis with pleural or pericardial effusion (appropriate antituberculous chemotherapy must be used concurrently when treating any tuberculosis complications); trichinosis with neurologic or myocardial involvement; acute or chronic solid organ rejection (with or without other agents). Launch Date 1955
Acute leukemia 32 Sources: https://www.drugs.com/pro/prednisolone-sodium-phosphate-oral-solution.html	Primary	Approved 8583	Prednisolone Approved Use Prednisolone Sodium Phosphate Oral Solution (10 mg Prednisolone per 5 mL) is indicated in the following conditions: 1. Allergic States Control of severe or incapacitating allergic conditions intractable to adequate trials of conventional treatment in adult and pediatric populations with: seasonal or perennial allergic rhinitis; asthma; contact dermatitis; atopic dermatitis; serum sickness; drug hypersensitivity reactions. 2. Dermatologic Diseases Pemphigus; bullous dermatitis herpetiformis; severe erythema multiforme (Stevens-Johnson syndrome); exfoliative erythroderma; mycosis fungoides. 3. Edematous States To induce diuresis or remission of proteinuria in nephrotic syndrome in adults with lupus erythematosus and in adults and pediatric populations, with idiopathic nephrotic syndrome, without uremia. 4. Endocrine Disorders Primary or secondary adrenocortical insufficiency (hydrocortisone or cortisone is the first choice; synthetic analogs may be used in conjunction with mineralocorticoids where applicable; in infancy mineralocorticoid supplementation is of particular importance); congenital adrenal hyperplasia; hypercalcemia associated with cancer; nonsuppurative thyroiditis. 5. Gastrointestinal Diseases To tide the patient over a critical period of the disease in: ulcerative colitis; regional enteritis. 6. Hematologic Disorders Idiopathic thrombocytopenic purpura in adults; selected cases of secondary thrombocytopenia; acquired (autoimmune) hemolytic anemia; pure red cell aplasia; Diamond-Blackfan anemia. 7. Neoplastic Diseases For the treatment of acute leukemia and aggressive lymphomas in adults and children. 8. Nervous System Acute exacerbations of multiple sclerosis. 9. Ophthalmic Diseases Uveitis and ocular inflammatory conditions unresponsive to topical corticosteroids; temporal arteritis; sympathetic ophthalmia. 10. Respiratory Diseases Symptomatic sarcoidosis; idiopathic eosinophilic pneumonias; fulminating or disseminated pulmonary tuberculosis when used concurrently with appropriate antituberculous chemotherapy; asthma (as distinct from allergic asthma listed above under "Allergic States"), hypersensitivity pneumonitis, idiopathic pulmonary fibrosis, acute exacerbations of chronic obstructive pulmonary disease (COPD), and Pneumocystis carinii pneumonia (PCP) associated with hypoxemia occurring in an HIV (+) individual who is also under treatment with appropriate anti-PCP antibiotics. Studies support the efficacy of systemic corticosteroids for the treatment of these conditions: allergic bronchopulmonary aspergillosis, idiopathic bronchiolitis obliterans with organizing pneumonia. 11. Rheumatic Disorders As adjunctive therapy for short term administration (to tide the patient over an acute episode or exacerbation) in: psoriatic arthritis; rheumatoid arthritis, including juvenile rheumatoid arthritis (selected cases may require low dose maintenance therapy); ankylosing spondylitis; acute and subacute bursitis; acute nonspecific tenosynovitis; acute gouty arthritis; epicondylitis. For the treatment of systemic lupus erythematosus, dermatomyositis (polymyositis), polymyalgia rheumatica, Sjogren's syndrome, relapsing polychondritis, and certain cases of vasculitis. 12. Miscellaneous Tuberculous meningitis with subarachnoid block or impending block, tuberculosis with enlarged mediastinal lymph nodes causing respiratory difficulty, and tuberculosis with pleural or pericardial effusion (appropriate antituberculous chemotherapy must be used concurrently when treating any tuberculosis complications); trichinosis with neurologic or myocardial involvement; acute or chronic solid organ rejection (with or without other agents). Launch Date 1955
Multiple sclerosis 107 Sources: https://www.drugs.com/pro/prednisolone-sodium-phosphate-oral-solution.html	Primary	Approved 8583	Prednisolone Approved Use Prednisolone Sodium Phosphate Oral Solution (10 mg Prednisolone per 5 mL) is indicated in the following conditions: 1. Allergic States Control of severe or incapacitating allergic conditions intractable to adequate trials of conventional treatment in adult and pediatric populations with: seasonal or perennial allergic rhinitis; asthma; contact dermatitis; atopic dermatitis; serum sickness; drug hypersensitivity reactions. 2. Dermatologic Diseases Pemphigus; bullous dermatitis herpetiformis; severe erythema multiforme (Stevens-Johnson syndrome); exfoliative erythroderma; mycosis fungoides. 3. Edematous States To induce diuresis or remission of proteinuria in nephrotic syndrome in adults with lupus erythematosus and in adults and pediatric populations, with idiopathic nephrotic syndrome, without uremia. 4. Endocrine Disorders Primary or secondary adrenocortical insufficiency (hydrocortisone or cortisone is the first choice; synthetic analogs may be used in conjunction with mineralocorticoids where applicable; in infancy mineralocorticoid supplementation is of particular importance); congenital adrenal hyperplasia; hypercalcemia associated with cancer; nonsuppurative thyroiditis. 5. Gastrointestinal Diseases To tide the patient over a critical period of the disease in: ulcerative colitis; regional enteritis. 6. Hematologic Disorders Idiopathic thrombocytopenic purpura in adults; selected cases of secondary thrombocytopenia; acquired (autoimmune) hemolytic anemia; pure red cell aplasia; Diamond-Blackfan anemia. 7. Neoplastic Diseases For the treatment of acute leukemia and aggressive lymphomas in adults and children. 8. Nervous System Acute exacerbations of multiple sclerosis. 9. Ophthalmic Diseases Uveitis and ocular inflammatory conditions unresponsive to topical corticosteroids; temporal arteritis; sympathetic ophthalmia. 10. Respiratory Diseases Symptomatic sarcoidosis; idiopathic eosinophilic pneumonias; fulminating or disseminated pulmonary tuberculosis when used concurrently with appropriate antituberculous chemotherapy; asthma (as distinct from allergic asthma listed above under "Allergic States"), hypersensitivity pneumonitis, idiopathic pulmonary fibrosis, acute exacerbations of chronic obstructive pulmonary disease (COPD), and Pneumocystis carinii pneumonia (PCP) associated with hypoxemia occurring in an HIV (+) individual who is also under treatment with appropriate anti-PCP antibiotics. Studies support the efficacy of systemic corticosteroids for the treatment of these conditions: allergic bronchopulmonary aspergillosis, idiopathic bronchiolitis obliterans with organizing pneumonia. 11. Rheumatic Disorders As adjunctive therapy for short term administration (to tide the patient over an acute episode or exacerbation) in: psoriatic arthritis; rheumatoid arthritis, including juvenile rheumatoid arthritis (selected cases may require low dose maintenance therapy); ankylosing spondylitis; acute and subacute bursitis; acute nonspecific tenosynovitis; acute gouty arthritis; epicondylitis. For the treatment of systemic lupus erythematosus, dermatomyositis (polymyositis), polymyalgia rheumatica, Sjogren's syndrome, relapsing polychondritis, and certain cases of vasculitis. 12. Miscellaneous Tuberculous meningitis with subarachnoid block or impending block, tuberculosis with enlarged mediastinal lymph nodes causing respiratory difficulty, and tuberculosis with pleural or pericardial effusion (appropriate antituberculous chemotherapy must be used concurrently when treating any tuberculosis complications); trichinosis with neurologic or myocardial involvement; acute or chronic solid organ rejection (with or without other agents). Launch Date 1955
Uveitis 28 Sources: https://www.drugs.com/pro/prednisolone-sodium-phosphate-oral-solution.html	Primary	Approved 8583	Prednisolone Approved Use Prednisolone Sodium Phosphate Oral Solution (10 mg Prednisolone per 5 mL) is indicated in the following conditions: 1. Allergic States Control of severe or incapacitating allergic conditions intractable to adequate trials of conventional treatment in adult and pediatric populations with: seasonal or perennial allergic rhinitis; asthma; contact dermatitis; atopic dermatitis; serum sickness; drug hypersensitivity reactions. 2. Dermatologic Diseases Pemphigus; bullous dermatitis herpetiformis; severe erythema multiforme (Stevens-Johnson syndrome); exfoliative erythroderma; mycosis fungoides. 3. Edematous States To induce diuresis or remission of proteinuria in nephrotic syndrome in adults with lupus erythematosus and in adults and pediatric populations, with idiopathic nephrotic syndrome, without uremia. 4. Endocrine Disorders Primary or secondary adrenocortical insufficiency (hydrocortisone or cortisone is the first choice; synthetic analogs may be used in conjunction with mineralocorticoids where applicable; in infancy mineralocorticoid supplementation is of particular importance); congenital adrenal hyperplasia; hypercalcemia associated with cancer; nonsuppurative thyroiditis. 5. Gastrointestinal Diseases To tide the patient over a critical period of the disease in: ulcerative colitis; regional enteritis. 6. Hematologic Disorders Idiopathic thrombocytopenic purpura in adults; selected cases of secondary thrombocytopenia; acquired (autoimmune) hemolytic anemia; pure red cell aplasia; Diamond-Blackfan anemia. 7. Neoplastic Diseases For the treatment of acute leukemia and aggressive lymphomas in adults and children. 8. Nervous System Acute exacerbations of multiple sclerosis. 9. Ophthalmic Diseases Uveitis and ocular inflammatory conditions unresponsive to topical corticosteroids; temporal arteritis; sympathetic ophthalmia. 10. Respiratory Diseases Symptomatic sarcoidosis; idiopathic eosinophilic pneumonias; fulminating or disseminated pulmonary tuberculosis when used concurrently with appropriate antituberculous chemotherapy; asthma (as distinct from allergic asthma listed above under "Allergic States"), hypersensitivity pneumonitis, idiopathic pulmonary fibrosis, acute exacerbations of chronic obstructive pulmonary disease (COPD), and Pneumocystis carinii pneumonia (PCP) associated with hypoxemia occurring in an HIV (+) individual who is also under treatment with appropriate anti-PCP antibiotics. Studies support the efficacy of systemic corticosteroids for the treatment of these conditions: allergic bronchopulmonary aspergillosis, idiopathic bronchiolitis obliterans with organizing pneumonia. 11. Rheumatic Disorders As adjunctive therapy for short term administration (to tide the patient over an acute episode or exacerbation) in: psoriatic arthritis; rheumatoid arthritis, including juvenile rheumatoid arthritis (selected cases may require low dose maintenance therapy); ankylosing spondylitis; acute and subacute bursitis; acute nonspecific tenosynovitis; acute gouty arthritis; epicondylitis. For the treatment of systemic lupus erythematosus, dermatomyositis (polymyositis), polymyalgia rheumatica, Sjogren's syndrome, relapsing polychondritis, and certain cases of vasculitis. 12. Miscellaneous Tuberculous meningitis with subarachnoid block or impending block, tuberculosis with enlarged mediastinal lymph nodes causing respiratory difficulty, and tuberculosis with pleural or pericardial effusion (appropriate antituberculous chemotherapy must be used concurrently when treating any tuberculosis complications); trichinosis with neurologic or myocardial involvement; acute or chronic solid organ rejection (with or without other agents). Launch Date 1955
Symptomatic sarcoidosis 22 Sources: https://www.drugs.com/pro/prednisolone-sodium-phosphate-oral-solution.html	Primary	Approved 8583	Prednisolone Approved Use Prednisolone Sodium Phosphate Oral Solution (10 mg Prednisolone per 5 mL) is indicated in the following conditions: 1. Allergic States Control of severe or incapacitating allergic conditions intractable to adequate trials of conventional treatment in adult and pediatric populations with: seasonal or perennial allergic rhinitis; asthma; contact dermatitis; atopic dermatitis; serum sickness; drug hypersensitivity reactions. 2. Dermatologic Diseases Pemphigus; bullous dermatitis herpetiformis; severe erythema multiforme (Stevens-Johnson syndrome); exfoliative erythroderma; mycosis fungoides. 3. Edematous States To induce diuresis or remission of proteinuria in nephrotic syndrome in adults with lupus erythematosus and in adults and pediatric populations, with idiopathic nephrotic syndrome, without uremia. 4. Endocrine Disorders Primary or secondary adrenocortical insufficiency (hydrocortisone or cortisone is the first choice; synthetic analogs may be used in conjunction with mineralocorticoids where applicable; in infancy mineralocorticoid supplementation is of particular importance); congenital adrenal hyperplasia; hypercalcemia associated with cancer; nonsuppurative thyroiditis. 5. Gastrointestinal Diseases To tide the patient over a critical period of the disease in: ulcerative colitis; regional enteritis. 6. Hematologic Disorders Idiopathic thrombocytopenic purpura in adults; selected cases of secondary thrombocytopenia; acquired (autoimmune) hemolytic anemia; pure red cell aplasia; Diamond-Blackfan anemia. 7. Neoplastic Diseases For the treatment of acute leukemia and aggressive lymphomas in adults and children. 8. Nervous System Acute exacerbations of multiple sclerosis. 9. Ophthalmic Diseases Uveitis and ocular inflammatory conditions unresponsive to topical corticosteroids; temporal arteritis; sympathetic ophthalmia. 10. Respiratory Diseases Symptomatic sarcoidosis; idiopathic eosinophilic pneumonias; fulminating or disseminated pulmonary tuberculosis when used concurrently with appropriate antituberculous chemotherapy; asthma (as distinct from allergic asthma listed above under "Allergic States"), hypersensitivity pneumonitis, idiopathic pulmonary fibrosis, acute exacerbations of chronic obstructive pulmonary disease (COPD), and Pneumocystis carinii pneumonia (PCP) associated with hypoxemia occurring in an HIV (+) individual who is also under treatment with appropriate anti-PCP antibiotics. Studies support the efficacy of systemic corticosteroids for the treatment of these conditions: allergic bronchopulmonary aspergillosis, idiopathic bronchiolitis obliterans with organizing pneumonia. 11. Rheumatic Disorders As adjunctive therapy for short term administration (to tide the patient over an acute episode or exacerbation) in: psoriatic arthritis; rheumatoid arthritis, including juvenile rheumatoid arthritis (selected cases may require low dose maintenance therapy); ankylosing spondylitis; acute and subacute bursitis; acute nonspecific tenosynovitis; acute gouty arthritis; epicondylitis. For the treatment of systemic lupus erythematosus, dermatomyositis (polymyositis), polymyalgia rheumatica, Sjogren's syndrome, relapsing polychondritis, and certain cases of vasculitis. 12. Miscellaneous Tuberculous meningitis with subarachnoid block or impending block, tuberculosis with enlarged mediastinal lymph nodes causing respiratory difficulty, and tuberculosis with pleural or pericardial effusion (appropriate antituberculous chemotherapy must be used concurrently when treating any tuberculosis complications); trichinosis with neurologic or myocardial involvement; acute or chronic solid organ rejection (with or without other agents). Launch Date 1955
Rheumatic diseases 31 Sources: https://www.drugs.com/pro/prednisolone-sodium-phosphate-oral-solution.html	Primary	Approved 8583	Prednisolone Approved Use Prednisolone Sodium Phosphate Oral Solution (10 mg Prednisolone per 5 mL) is indicated in the following conditions: 1. Allergic States Control of severe or incapacitating allergic conditions intractable to adequate trials of conventional treatment in adult and pediatric populations with: seasonal or perennial allergic rhinitis; asthma; contact dermatitis; atopic dermatitis; serum sickness; drug hypersensitivity reactions. 2. Dermatologic Diseases Pemphigus; bullous dermatitis herpetiformis; severe erythema multiforme (Stevens-Johnson syndrome); exfoliative erythroderma; mycosis fungoides. 3. Edematous States To induce diuresis or remission of proteinuria in nephrotic syndrome in adults with lupus erythematosus and in adults and pediatric populations, with idiopathic nephrotic syndrome, without uremia. 4. Endocrine Disorders Primary or secondary adrenocortical insufficiency (hydrocortisone or cortisone is the first choice; synthetic analogs may be used in conjunction with mineralocorticoids where applicable; in infancy mineralocorticoid supplementation is of particular importance); congenital adrenal hyperplasia; hypercalcemia associated with cancer; nonsuppurative thyroiditis. 5. Gastrointestinal Diseases To tide the patient over a critical period of the disease in: ulcerative colitis; regional enteritis. 6. Hematologic Disorders Idiopathic thrombocytopenic purpura in adults; selected cases of secondary thrombocytopenia; acquired (autoimmune) hemolytic anemia; pure red cell aplasia; Diamond-Blackfan anemia. 7. Neoplastic Diseases For the treatment of acute leukemia and aggressive lymphomas in adults and children. 8. Nervous System Acute exacerbations of multiple sclerosis. 9. Ophthalmic Diseases Uveitis and ocular inflammatory conditions unresponsive to topical corticosteroids; temporal arteritis; sympathetic ophthalmia. 10. Respiratory Diseases Symptomatic sarcoidosis; idiopathic eosinophilic pneumonias; fulminating or disseminated pulmonary tuberculosis when used concurrently with appropriate antituberculous chemotherapy; asthma (as distinct from allergic asthma listed above under "Allergic States"), hypersensitivity pneumonitis, idiopathic pulmonary fibrosis, acute exacerbations of chronic obstructive pulmonary disease (COPD), and Pneumocystis carinii pneumonia (PCP) associated with hypoxemia occurring in an HIV (+) individual who is also under treatment with appropriate anti-PCP antibiotics. Studies support the efficacy of systemic corticosteroids for the treatment of these conditions: allergic bronchopulmonary aspergillosis, idiopathic bronchiolitis obliterans with organizing pneumonia. 11. Rheumatic Disorders As adjunctive therapy for short term administration (to tide the patient over an acute episode or exacerbation) in: psoriatic arthritis; rheumatoid arthritis, including juvenile rheumatoid arthritis (selected cases may require low dose maintenance therapy); ankylosing spondylitis; acute and subacute bursitis; acute nonspecific tenosynovitis; acute gouty arthritis; epicondylitis. For the treatment of systemic lupus erythematosus, dermatomyositis (polymyositis), polymyalgia rheumatica, Sjogren's syndrome, relapsing polychondritis, and certain cases of vasculitis. 12. Miscellaneous Tuberculous meningitis with subarachnoid block or impending block, tuberculosis with enlarged mediastinal lymph nodes causing respiratory difficulty, and tuberculosis with pleural or pericardial effusion (appropriate antituberculous chemotherapy must be used concurrently when treating any tuberculosis complications); trichinosis with neurologic or myocardial involvement; acute or chronic solid organ rejection (with or without other agents). Launch Date 1955
Inflammation and pain 22 Sources: (2013) Arthritis: New Insights for the Healthcare Professional, page 345, retrieved from: https://books.google.ru/books?id=YvMIwDn3a20C	Palliative	Approved 8583	Sixtysix-20 Approved Use Antiinflammatory agent
Atopic dermatitis 64 Sources: http://www.accessdata.fda.gov/drugsatfda_docs/label/2013/202020s003lbl.pdf	Palliative	Approved 8583	RAYOS Approved Use RAYOS is a corticosteroid indicated as an anti-inflammatory or immunosuppressive agent for certain allergic, dermatologic, gastrointestinal, hematologic, ophthalmologic, nervous system, renal, respiratory, rheumatologic, specific infectious diseases or conditions and organ transplantation; for the treatment of certain endocrine conditions; for palliation of certain neoplastic conditions Launch Date 2012
Severe erythema multiforme (Stevens-Johnson syndrome) 22 Sources: http://www.accessdata.fda.gov/drugsatfda_docs/label/2013/202020s003lbl.pdf	Palliative	Approved 8583	RAYOS Approved Use RAYOS is a corticosteroid indicated as an anti-inflammatory or immunosuppressive agent for certain allergic, dermatologic, gastrointestinal, hematologic, ophthalmologic, nervous system, renal, respiratory, rheumatologic, specific infectious diseases or conditions and organ transplantation; for the treatment of certain endocrine conditions; for palliation of certain neoplastic conditions Launch Date 2012
Congenital adrenal hyperplasia 62 Sources: http://www.accessdata.fda.gov/drugsatfda_docs/label/2013/202020s003lbl.pdf	Palliative	Approved 8583	RAYOS Approved Use RAYOS is a corticosteroid indicated as an anti-inflammatory or immunosuppressive agent for certain allergic, dermatologic, gastrointestinal, hematologic, ophthalmologic, nervous system, renal, respiratory, rheumatologic, specific infectious diseases or conditions and organ transplantation; for the treatment of certain endocrine conditions; for palliation of certain neoplastic conditions Launch Date 2012
Crohn's disease 64 Sources: http://www.accessdata.fda.gov/drugsatfda_docs/label/2013/202020s003lbl.pdf	Palliative	Approved 8583	RAYOS Approved Use RAYOS is a corticosteroid indicated as an anti-inflammatory or immunosuppressive agent for certain allergic, dermatologic, gastrointestinal, hematologic, ophthalmologic, nervous system, renal, respiratory, rheumatologic, specific infectious diseases or conditions and organ transplantation; for the treatment of certain endocrine conditions; for palliation of certain neoplastic conditions Launch Date 2012
Diamond-Blackfan anemia 24 Sources: http://www.accessdata.fda.gov/drugsatfda_docs/label/2013/202020s003lbl.pdf	Palliative	Approved 8583	RAYOS Approved Use RAYOS is a corticosteroid indicated as an anti-inflammatory or immunosuppressive agent for certain allergic, dermatologic, gastrointestinal, hematologic, ophthalmologic, nervous system, renal, respiratory, rheumatologic, specific infectious diseases or conditions and organ transplantation; for the treatment of certain endocrine conditions; for palliation of certain neoplastic conditions Launch Date 2012
Aggressive lymphoma 24 Sources: http://www.accessdata.fda.gov/drugsatfda_docs/label/2013/202020s003lbl.pdf	Palliative	Approved 8583	RAYOS Approved Use RAYOS is a corticosteroid indicated as an anti-inflammatory or immunosuppressive agent for certain allergic, dermatologic, gastrointestinal, hematologic, ophthalmologic, nervous system, renal, respiratory, rheumatologic, specific infectious diseases or conditions and organ transplantation; for the treatment of certain endocrine conditions; for palliation of certain neoplastic conditions Launch Date 2012
Allergic conjunctivitis 101 Sources: http://www.accessdata.fda.gov/drugsatfda_docs/label/2007/017469s040lbl.pdf	Primary	Approved 8583	OMNIPRED Approved Use Steroid responsive inflammatory conditions of the palpebral and bulbar conjunctiva, cornea, and anterior segment of the globe such as allergic conjunctivitis, acne rosacea, superficial punctate keratitis, herpes zoster keratitis, iritis, cyclitis, selected infective conjunctivitides, when the inherent hazard of steroid use is accepted to obtain an advisable diminution in edema and inflammation; corneal injury from chemical, radiation, or thermal burns, or penetration of foreign bodies. Launch Date 1973
Acne rosacea 44 Sources: http://www.accessdata.fda.gov/drugsatfda_docs/label/2007/017469s040lbl.pdf	Primary	Approved 8583	OMNIPRED Approved Use Steroid responsive inflammatory conditions of the palpebral and bulbar conjunctiva, cornea, and anterior segment of the globe such as allergic conjunctivitis, acne rosacea, superficial punctate keratitis, herpes zoster keratitis, iritis, cyclitis, selected infective conjunctivitides, when the inherent hazard of steroid use is accepted to obtain an advisable diminution in edema and inflammation; corneal injury from chemical, radiation, or thermal burns, or penetration of foreign bodies. Launch Date 1973
Superficial punctate keratitis 43 Sources: http://www.accessdata.fda.gov/drugsatfda_docs/label/2007/017469s040lbl.pdf	Primary	Approved 8583	OMNIPRED Approved Use Steroid responsive inflammatory conditions of the palpebral and bulbar conjunctiva, cornea, and anterior segment of the globe such as allergic conjunctivitis, acne rosacea, superficial punctate keratitis, herpes zoster keratitis, iritis, cyclitis, selected infective conjunctivitides, when the inherent hazard of steroid use is accepted to obtain an advisable diminution in edema and inflammation; corneal injury from chemical, radiation, or thermal burns, or penetration of foreign bodies. Launch Date 1973
Herpes zoster keratitis 44 Sources: http://www.accessdata.fda.gov/drugsatfda_docs/label/2007/017469s040lbl.pdf	Primary	Approved 8583	OMNIPRED Approved Use Steroid responsive inflammatory conditions of the palpebral and bulbar conjunctiva, cornea, and anterior segment of the globe such as allergic conjunctivitis, acne rosacea, superficial punctate keratitis, herpes zoster keratitis, iritis, cyclitis, selected infective conjunctivitides, when the inherent hazard of steroid use is accepted to obtain an advisable diminution in edema and inflammation; corneal injury from chemical, radiation, or thermal burns, or penetration of foreign bodies. Launch Date 1973
Iritis 43 Sources: http://www.accessdata.fda.gov/drugsatfda_docs/label/2007/017469s040lbl.pdf	Primary	Approved 8583	OMNIPRED Approved Use Steroid responsive inflammatory conditions of the palpebral and bulbar conjunctiva, cornea, and anterior segment of the globe such as allergic conjunctivitis, acne rosacea, superficial punctate keratitis, herpes zoster keratitis, iritis, cyclitis, selected infective conjunctivitides, when the inherent hazard of steroid use is accepted to obtain an advisable diminution in edema and inflammation; corneal injury from chemical, radiation, or thermal burns, or penetration of foreign bodies. Launch Date 1973
Anaphylaxis 47 Sources: https://medikamio.com/de-de/medikamente/prednisolut-1000-mg/pil	Curative	Approved 8583	Prednisolut Approved Use Prednisolut is indicated in shock and emergency medicine: Shock due to a severe allergic reaction (anaphylactic shock), after previous treatment with epinephrine, progressive forms of allergic reactions in insect bites and snake bites
Brain edema 22 Sources: https://medikamio.com/de-de/medikamente/prednisolut-1000-mg/pil	Primary	Approved 8583	Prednisolut Approved Use Brain swelling (brain edema), triggered by brain tumor, neurosurgery, brain abscess, bacterial meningitis (meningitis).
Acute asthma attack 22 Sources: https://medikamio.com/de-de/medikamente/prednisolut-1000-mg/pil	Primary	Approved 8583	Prednisolut Approved Use Prednisolut is indicated to treat acute asthma attack, pulmonary edema by inhalation of toxic substances such as chlorga's, isocyanates, hydrogen sulphide, phosgene, nitrose gas, ozone, also nitrogen oxide, by gastric juice aspiration, and by drown.
Pulmonary edema 25 Sources: https://medikamio.com/de-de/medikamente/prednisolut-1000-mg/pil	Primary	Approved 8583	Prednisolut Approved Use Prednisolut is indicated to treat acute asthma attack, pulmonary edema by inhalation of toxic substances such as chlorga's, isocyanates, hydrogen sulphide, phosgene, nitrose gas, ozone, also nitrogen oxide, by gastric juice aspiration, and by drown.
Rheumatoid arthritis 320 Sources: https://medikamio.com/de-de/medikamente/prednisolut-1000-mg/pil	Primary	Approved 8583	Prednisolut Approved Use Prednisolut is indicated for treatment of severe / life-threatening situations in the following rheumatic diseases: rheumatoid arthritis and still syndrome, felty syndrome, polymyalgia rheumatica, systemic juvenile idiopathic arthritis (eg breast disease, seropositive polyarthritis), collagenoses, vasculitides, rheumatic fever.

C_max

Value	Dose	Analyte	Population
0.054 mg/L EXPERIMENT https://pubmed.ncbi.nlm.nih.gov/8513854/	60 mg single, enteral dose: 60 mg route of administration: Enteral experiment type: SINGLE co-administered:	PREDNISONE plasma	Homo sapiens population: HEALTHY age: ADULT sex: MALE food status: FASTED
33.2 ng/mL EXPERIMENT https://pubmed.ncbi.nlm.nih.gov/12616672/	30 mg single, oral dose: 30 mg route of administration: Oral experiment type: SINGLE co-administered:	PREDNISONE plasma	Homo sapiens population: HEALTHY age: ADULT sex: MALE food status: FASTED
41.8 ng/mL EXPERIMENT https://pubmed.ncbi.nlm.nih.gov/29329497/	40 mg single, oral dose: 40 mg route of administration: Oral experiment type: SINGLE co-administered:	PREDNISONE plasma	Homo sapiens population: HEALTHY age: ADULT sex: FEMALE / MALE food status: FASTED
43.9 ng/mL EXPERIMENT https://pubmed.ncbi.nlm.nih.gov/29329497/	40 mg single, oral dose: 40 mg route of administration: Oral experiment type: SINGLE co-administered:	PREDNISONE plasma	Homo sapiens population: HEALTHY age: ADULT sex: FEMALE / MALE food status: FASTED
15.4 μg/L EXPERIMENT https://www.ncbi.nlm.nih.gov/pubmed/17925494	20 mg single, oral dose: 20 mg route of administration: Oral experiment type: SINGLE co-administered:	PREDNISONE plasma	Homo sapiens population: HEALTHY age: ADULT sex: MALE food status: FED
420.91 ng/mL DRUG LABEL https://www.accessdata.fda.gov/drugsatfda_docs/label/2010/021959s004lbl.pdf	30 mg single, oral dose: 30 mg route of administration: Oral experiment type: SINGLE co-administered:	PREDNISOLONE plasma	Homo sapiens population: HEALTHY age: ADULT sex: UNKNOWN food status: FASTED
14.43 ng/mL DRUG LABEL https://www.pmda.go.jp/PmdaSearch/iyakuDetail/ResultDataSetPDF/672212_2456402C1044_3_03#page=4	40 mg single, intramuscular dose: 40 mg route of administration: Intramuscular experiment type: SINGLE co-administered:	PREDNISOLONE blood	Homo sapiens population: UNKNOWN age: UNKNOWN sex: UNKNOWN food status: UNKNOWN
86 μg/dL OTHER GOV'T https://www.info.pmda.go.jp/go/interview/2/343018_2456405D1027_2_016_1F.pdf#page=31	20 mg single, intramuscular dose: 20 mg route of administration: Intramuscular experiment type: SINGLE co-administered:	PREDNISOLONE HEMISUCCINATE serum	Homo sapiens population: HEALTHY age: ADULT sex: UNKNOWN food status: UNKNOWN
36 μg/dL OTHER GOV'T https://www.info.pmda.go.jp/go/interview/2/343018_2456405D1027_2_016_1F.pdf#page=31	20 mg single, intramuscular dose: 20 mg route of administration: Intramuscular experiment type: SINGLE co-administered:	PREDNISOLONE serum	Homo sapiens population: HEALTHY age: ADULT sex: UNKNOWN food status: UNKNOWN

AUC

Value	Dose	Analyte	Population
0.484 mg × h/L EXPERIMENT https://pubmed.ncbi.nlm.nih.gov/8513854/	60 mg single, enteral dose: 60 mg route of administration: Enteral experiment type: SINGLE co-administered:	PREDNISONE plasma	Homo sapiens population: HEALTHY age: ADULT sex: MALE food status: FASTED
298 ng × h/mL EXPERIMENT https://pubmed.ncbi.nlm.nih.gov/12616672/	30 mg single, oral dose: 30 mg route of administration: Oral experiment type: SINGLE co-administered:	PREDNISONE plasma	Homo sapiens population: HEALTHY age: ADULT sex: MALE food status: FASTED
358 ng × h/mL EXPERIMENT https://pubmed.ncbi.nlm.nih.gov/29329497/	40 mg single, oral dose: 40 mg route of administration: Oral experiment type: SINGLE co-administered:	PREDNISONE plasma	Homo sapiens population: HEALTHY age: ADULT sex: FEMALE / MALE food status: FASTED
387 ng × h/mL EXPERIMENT https://pubmed.ncbi.nlm.nih.gov/29329497/	40 mg single, oral dose: 40 mg route of administration: Oral experiment type: SINGLE co-administered:	PREDNISONE plasma	Homo sapiens population: HEALTHY age: ADULT sex: FEMALE / MALE food status: FASTED
97 μg × h/L EXPERIMENT https://www.ncbi.nlm.nih.gov/pubmed/17925494	20 mg single, oral dose: 20 mg route of administration: Oral experiment type: SINGLE co-administered:	PREDNISONE plasma	Homo sapiens population: HEALTHY age: ADULT sex: MALE food status: FED
2408.1 ng × h/mL DRUG LABEL https://www.accessdata.fda.gov/drugsatfda_docs/label/2010/021959s004lbl.pdf	30 mg single, oral dose: 30 mg route of administration: Oral experiment type: SINGLE co-administered:	PREDNISOLONE plasma	Homo sapiens population: HEALTHY age: ADULT sex: UNKNOWN food status: FASTED
0.025 μg × h/mL EXPERIMENT https://pubmed.ncbi.nlm.nih.gov/4084667/	1200 mg single, intravenous dose: 1200 mg route of administration: Intravenous experiment type: SINGLE co-administered:	PREDNISOLONE HEMISUCCINATE plasma	Homo sapiens population: HEALTHY age: ADULT sex: UNKNOWN food status: UNKNOWN
0.0173 μg × h/mL EXPERIMENT https://pubmed.ncbi.nlm.nih.gov/4084667/	75 mg single, intravenous dose: 75 mg route of administration: Intravenous experiment type: SINGLE co-administered:	PREDNISOLONE HEMISUCCINATE plasma	Homo sapiens population: HEALTHY age: ADULT sex: UNKNOWN food status: UNKNOWN
0.085 μg × h/mL EXPERIMENT https://pubmed.ncbi.nlm.nih.gov/4084667/	1200 mg single, intravenous dose: 1200 mg route of administration: Intravenous experiment type: SINGLE co-administered:	PREDNISOLONE plasma	Homo sapiens population: HEALTHY age: ADULT sex: UNKNOWN food status: UNKNOWN
0.0601 μg × h/mL EXPERIMENT https://pubmed.ncbi.nlm.nih.gov/4084667/	75 mg single, intravenous dose: 75 mg route of administration: Intravenous experiment type: SINGLE co-administered:	PREDNISOLONE plasma	Homo sapiens population: HEALTHY age: ADULT sex: UNKNOWN food status: UNKNOWN

T_1/2

Value	Dose	Analyte	Population
5.11 h EXPERIMENT https://pubmed.ncbi.nlm.nih.gov/8513854/	60 mg single, enteral dose: 60 mg route of administration: Enteral experiment type: SINGLE co-administered:	PREDNISONE plasma	Homo sapiens population: HEALTHY age: ADULT sex: MALE food status: FASTED
3.3 h EXPERIMENT https://pubmed.ncbi.nlm.nih.gov/29329497/	40 mg single, oral dose: 40 mg route of administration: Oral experiment type: SINGLE co-administered:	PREDNISONE plasma	Homo sapiens population: HEALTHY age: ADULT sex: FEMALE / MALE food status: FASTED
3.6 h EXPERIMENT https://pubmed.ncbi.nlm.nih.gov/29329497/	40 mg single, oral dose: 40 mg route of administration: Oral experiment type: SINGLE co-administered:	PREDNISONE plasma	Homo sapiens population: HEALTHY age: ADULT sex: FEMALE / MALE food status: FASTED
3.85 h EXPERIMENT https://www.ncbi.nlm.nih.gov/pubmed/17925494	20 mg single, oral dose: 20 mg route of administration: Oral experiment type: SINGLE co-administered:	PREDNISONE plasma	Homo sapiens population: HEALTHY age: ADULT sex: MALE food status: FED
2.6 h DRUG LABEL https://www.accessdata.fda.gov/drugsatfda_docs/label/2010/021959s004lbl.pdf	30 mg single, oral dose: 30 mg route of administration: Oral experiment type: SINGLE co-administered:	PREDNISOLONE plasma	Homo sapiens population: HEALTHY age: ADULT sex: UNKNOWN food status: FASTED
4 h OTHER https://www.pdr.net/drug-summary/Omnipred-prednisolone-acetate-1102.1749#15		PREDNISOLONE plasma	Homo sapiens
30 min OTHER GOV'T https://www.info.pmda.go.jp/go/interview/2/343018_2456405D1027_2_016_1F.pdf#page=31	20 mg single, intramuscular dose: 20 mg route of administration: Intramuscular experiment type: SINGLE co-administered:	PREDNISOLONE HEMISUCCINATE serum	Homo sapiens population: HEALTHY age: ADULT sex: UNKNOWN food status: UNKNOWN
25 min EXPERIMENT https://pubmed.ncbi.nlm.nih.gov/4084667/	1200 mg single, intravenous dose: 1200 mg route of administration: Intravenous experiment type: SINGLE co-administered:	PREDNISOLONE HEMISUCCINATE plasma	Homo sapiens population: HEALTHY age: ADULT sex: UNKNOWN food status: UNKNOWN
18 min EXPERIMENT https://pubmed.ncbi.nlm.nih.gov/4084667/	75 mg single, intravenous dose: 75 mg route of administration: Intravenous experiment type: SINGLE co-administered:	PREDNISOLONE HEMISUCCINATE plasma	Homo sapiens population: HEALTHY age: ADULT sex: UNKNOWN food status: UNKNOWN
3.7 h EXPERIMENT https://pubmed.ncbi.nlm.nih.gov/4084667/	1200 mg single, intravenous dose: 1200 mg route of administration: Intravenous experiment type: SINGLE co-administered:	PREDNISOLONE plasma	Homo sapiens population: HEALTHY age: ADULT sex: UNKNOWN food status: UNKNOWN
3.5 h EXPERIMENT https://pubmed.ncbi.nlm.nih.gov/4084667/	75 mg single, intravenous dose: 75 mg route of administration: Intravenous experiment type: SINGLE co-administered:	PREDNISOLONE plasma	Homo sapiens population: HEALTHY age: ADULT sex: UNKNOWN food status: UNKNOWN

F_unbound

Value	Dose	Analyte	Population
50% EXPERIMENT https://www.ncbi.nlm.nih.gov/pubmed/2199128		PREDNISONE plasma	Homo sapiens population: UNKNOWN age: UNKNOWN sex: UNKNOWN food status: UNKNOWN
20% DRUG LABEL https://www.accessdata.fda.gov/drugsatfda_docs/label/2010/021959s004lbl.pdf	30 mg single, oral dose: 30 mg route of administration: Oral experiment type: SINGLE co-administered:	PREDNISOLONE plasma	Homo sapiens population: HEALTHY age: ADULT sex: UNKNOWN food status: FASTED
10% OTHER https://www.pdr.net/drug-summary/Omnipred-prednisolone-acetate-1102.1749#15		PREDNISOLONE plasma	Homo sapiens
23% EXPERIMENT https://pubmed.ncbi.nlm.nih.gov/4084667/	75 mg single, intravenous dose: 75 mg route of administration: Intravenous experiment type: SINGLE co-administered:	PREDNISOLONE plasma	Homo sapiens population: HEALTHY age: ADULT sex: UNKNOWN food status: UNKNOWN

Doses

Dose	Population	Adverse events
100 mg 1 times / day multiple, oral Highest studied dose Dose: 100 mg, 1 times / day Route: oral Route: multiple Dose: 100 mg, 1 times / day Sources: https://doi.org/10.1016/B978-0-12-385157-4.00633-3 https://pubmed.ncbi.nlm.nih.gov/33663183	unhealthy, adult Health Status: unhealthy Age Group: adult Sources: https://doi.org/10.1016/B978-0-12-385157-4.00633-3 https://pubmed.ncbi.nlm.nih.gov/33663183	Sources: https://doi.org/10.1016/B978-0-12-385157-4.00633-3 https://pubmed.ncbi.nlm.nih.gov/33663183
5 mg 1 times / day steady, oral Recommended Dose: 5 mg, 1 times / day Route: oral Route: steady Dose: 5 mg, 1 times / day Sources: https://www.accessdata.fda.gov/drugsatfda_docs/nda/2012/202020Orig1s000MedR.pdf	unhealthy, adult Health Status: unhealthy Age Group: adult Sources: https://www.accessdata.fda.gov/drugsatfda_docs/nda/2012/202020Orig1s000MedR.pdf	Disc. AE: Vertigo, Abdominal pain upper... AEs leading to discontinuation/dose reduction: Vertigo (1%) Abdominal pain upper (1%) Gastroesophageal reflux disease (1%) Intestinal functional disorder (1%) Nausea (1%) Dizziness (1%) Aphasia (1%) Headache (1%) Renal pain (1%) Sources: https://www.accessdata.fda.gov/drugsatfda_docs/nda/2012/202020Orig1s000MedR.pdf
1 % 4 times / day multiple, ophthalmic Recommended Dose: 1 %, 4 times / day Route: ophthalmic Route: multiple Dose: 1 %, 4 times / day Sources: https://pubmed.ncbi.nlm.nih.gov/17762913/	unhealthy, ADULT Health Status: unhealthy Age Group: ADULT Sex: M+F Food Status: UNKNOWN Sources: https://pubmed.ncbi.nlm.nih.gov/17762913/	Sources: https://pubmed.ncbi.nlm.nih.gov/17762913/

AEs

AE	Significance	Dose	Population
Abdominal pain upper	1% Disc. AE	5 mg 1 times / day steady, oral Recommended Dose: 5 mg, 1 times / day Route: oral Route: steady Dose: 5 mg, 1 times / day Sources: https://www.accessdata.fda.gov/drugsatfda_docs/nda/2012/202020Orig1s000MedR.pdf	unhealthy, adult Health Status: unhealthy Age Group: adult Sources: https://www.accessdata.fda.gov/drugsatfda_docs/nda/2012/202020Orig1s000MedR.pdf
Aphasia	1% Disc. AE	5 mg 1 times / day steady, oral Recommended Dose: 5 mg, 1 times / day Route: oral Route: steady Dose: 5 mg, 1 times / day Sources: https://www.accessdata.fda.gov/drugsatfda_docs/nda/2012/202020Orig1s000MedR.pdf	unhealthy, adult Health Status: unhealthy Age Group: adult Sources: https://www.accessdata.fda.gov/drugsatfda_docs/nda/2012/202020Orig1s000MedR.pdf
Dizziness	1% Disc. AE	5 mg 1 times / day steady, oral Recommended Dose: 5 mg, 1 times / day Route: oral Route: steady Dose: 5 mg, 1 times / day Sources: https://www.accessdata.fda.gov/drugsatfda_docs/nda/2012/202020Orig1s000MedR.pdf	unhealthy, adult Health Status: unhealthy Age Group: adult Sources: https://www.accessdata.fda.gov/drugsatfda_docs/nda/2012/202020Orig1s000MedR.pdf
Gastroesophageal reflux disease	1% Disc. AE	5 mg 1 times / day steady, oral Recommended Dose: 5 mg, 1 times / day Route: oral Route: steady Dose: 5 mg, 1 times / day Sources: https://www.accessdata.fda.gov/drugsatfda_docs/nda/2012/202020Orig1s000MedR.pdf	unhealthy, adult Health Status: unhealthy Age Group: adult Sources: https://www.accessdata.fda.gov/drugsatfda_docs/nda/2012/202020Orig1s000MedR.pdf
Headache	1% Disc. AE	5 mg 1 times / day steady, oral Recommended Dose: 5 mg, 1 times / day Route: oral Route: steady Dose: 5 mg, 1 times / day Sources: https://www.accessdata.fda.gov/drugsatfda_docs/nda/2012/202020Orig1s000MedR.pdf	unhealthy, adult Health Status: unhealthy Age Group: adult Sources: https://www.accessdata.fda.gov/drugsatfda_docs/nda/2012/202020Orig1s000MedR.pdf
Intestinal functional disorder	1% Disc. AE	5 mg 1 times / day steady, oral Recommended Dose: 5 mg, 1 times / day Route: oral Route: steady Dose: 5 mg, 1 times / day Sources: https://www.accessdata.fda.gov/drugsatfda_docs/nda/2012/202020Orig1s000MedR.pdf	unhealthy, adult Health Status: unhealthy Age Group: adult Sources: https://www.accessdata.fda.gov/drugsatfda_docs/nda/2012/202020Orig1s000MedR.pdf
Nausea	1% Disc. AE	5 mg 1 times / day steady, oral Recommended Dose: 5 mg, 1 times / day Route: oral Route: steady Dose: 5 mg, 1 times / day Sources: https://www.accessdata.fda.gov/drugsatfda_docs/nda/2012/202020Orig1s000MedR.pdf	unhealthy, adult Health Status: unhealthy Age Group: adult Sources: https://www.accessdata.fda.gov/drugsatfda_docs/nda/2012/202020Orig1s000MedR.pdf
Renal pain	1% Disc. AE	5 mg 1 times / day steady, oral Recommended Dose: 5 mg, 1 times / day Route: oral Route: steady Dose: 5 mg, 1 times / day Sources: https://www.accessdata.fda.gov/drugsatfda_docs/nda/2012/202020Orig1s000MedR.pdf	unhealthy, adult Health Status: unhealthy Age Group: adult Sources: https://www.accessdata.fda.gov/drugsatfda_docs/nda/2012/202020Orig1s000MedR.pdf
Vertigo	1% Disc. AE	5 mg 1 times / day steady, oral Recommended Dose: 5 mg, 1 times / day Route: oral Route: steady Dose: 5 mg, 1 times / day Sources: https://www.accessdata.fda.gov/drugsatfda_docs/nda/2012/202020Orig1s000MedR.pdf	unhealthy, adult Health Status: unhealthy Age Group: adult Sources: https://www.accessdata.fda.gov/drugsatfda_docs/nda/2012/202020Orig1s000MedR.pdf

Overview

CYP3A4	CYP2C9	CYP2D6	hERG

OverviewOther

Other Inhibitor	Other Substrate	Other Inducer
	11-beta-HSD2 48 11-beta-HSD1 33 P-gp 2052	P-gp 301 BCRP 101 MRP1 74 MRP4 53 MRP5 45 ABCC12 43 MRP2 146 MRP3 83

Drug as perpetrator

Target	Modality	Activity
ABCC12 43	inducer 1966 Sources: https://www.sciencedirect.com/science/article/pii/S0143400412002895 Page: -	no
BCRP 985	inducer 1966 Sources: https://www.sciencedirect.com/science/article/pii/S0143400412002895 Page: -	no
MRP1 232	inducer 1966 Sources: https://www.sciencedirect.com/science/article/pii/S0143400412002895 Page: -	no
MRP3 326	inducer 1966 Sources: https://pubmed.ncbi.nlm.nih.gov/15979871/ Page: -	no
MRP4 345	inducer 1966 Sources: https://www.sciencedirect.com/science/article/pii/S0143400412002895 Page: -	no
MRP5 80	inducer 1966 Sources: https://www.sciencedirect.com/science/article/pii/S0143400412002895 Page: -	no
P-gp 1932	inducer 1966 Sources: https://www.sciencedirect.com/science/article/pii/S0143400412002895 Page: -	no
MRP2 625	inducer 1966 Sources: https://pubmed.ncbi.nlm.nih.gov/15979871/ Page: -	yes

Drug as victim

Target	Modality	Activity
11-beta-HSD2 48	substrate 4014 Sources: https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6349812/ Page: -	major
11-beta-HSD1 33	substrate 4014 Sources: https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6349812/ Page: -	minor
P-gp 2052	substrate 4014 Sources: https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6349812/ Page: -	yes

Sourcing

Vendor/Aggregator	ID	URL
ChEBI	CHEBI:8382	https://www.ebi.ac.uk/chebi/searchId.do?chebiId=CHEBI:8382
ChemicalBook	CB44844383	https://www.chemicalbook.com/ChemicalProductProperty_EN_CB44844383
ChemicalBook	CB6716222	https://www.chemicalbook.com/ChemicalProductProperty_EN_CB6716222
eMolecules	29549912	https://www.emolecules.com/cgi-bin/more?vid=29549912
eMolecules	29703823	https://www.emolecules.com/cgi-bin/more?vid=29703823
eMolecules	31411020	https://www.emolecules.com/cgi-bin/more?vid=31411020
eMolecules	494851	https://www.emolecules.com/cgi-bin/more?vid=494851
MolPort	MolPort-001-740-041	https://www.molport.com/shop/molecule-link/MolPort-001-740-041
Selleck Chemicals	Prednisone	http://www.selleckchem.com/products/Prednisone.html
ZINC	ZINC000003875357	http://zinc15.docking.org/substances/ZINC000003875357
ChEBI	CHEBI:8378	https://www.ebi.ac.uk/chebi/searchId.do?chebiId=CHEBI:8378
ChemicalBook	CB4109000	https://www.chemicalbook.com/ChemicalProductProperty_EN_CB4109000
eMolecules	30512726	https://www.emolecules.com/cgi-bin/more?vid=30512726
eMolecules	31411129	https://www.emolecules.com/cgi-bin/more?vid=31411129
eMolecules	36644749	https://www.emolecules.com/cgi-bin/more?vid=36644749
eMolecules	511677	https://www.emolecules.com/cgi-bin/more?vid=511677
MolPort	MolPort-002-507-147	https://www.molport.com/shop/molecule-link/MolPort-002-507-147
Selleck Chemicals	Prednisolone(Hydroretrocortine)	http://www.selleckchem.com/products/Prednisolone(Hydroretrocortine).html
ZINC	ZINC000003833821	http://zinc15.docking.org/substances/ZINC000003833821

PubMed

Title	Date	PubMed
Intravenous hydrocortisone hemisuccinate and prednisolone hemisuccinate.	1956 Dec	13371916
Cytogenetic studies in a patient with acute granulocytic leukemia of seven and one-half years duration.	1975 Nov	1058041
An unusual adverse reaction to self-medication with prednisone: an irrational crime during a fugue-state.	1976-1977	1052090
Spontaneous aortic rupture associated with chronic steroid therapy for rheumatoid arthritis in two cases.	1979 Feb	105598
Role of platelet-activating factor in ulcerative colitis. Enhanced production during active disease and inhibition by sulfasalazine and prednisolone.	1988 Nov	2901995
Comparative study of availability of prednisolone after intestinal infusion of prednisolone metasulfobenzoate and prednisone.	1993	8513854
Prednisone is more effective than prednisolone metasulfobenzoate in the treatment of bullous pemphigoid.	1999 Jan	9923789
Low-dose oral pulse methotrexate as monotherapy in elderly patients with bullous pemphigoid.	1999 May	10321603
Low-dose vincristine-associated bilateral vocal cord paralysis.	1999 Oct	10578547
Lamotrigine as prophylaxis against steroid-induced mania.	1999 Oct	10549692
Delayed generalized allergic reactions to corticosteroids.	2000	10894975
Influence of cyclosporin A on radiological progression in early rheumatoid arthritis patients: a 42-month prospective study.	2000	10776690
Interstitial nephritis in children with Crohn's disease.	2000 Apr	10791141
Mesalamine-induced chest pain: a case report.	2000 May	10833545
Cognitive sequelae in children treated for acute lymphoblastic leukemia with dexamethasone or prednisone.	2000 May-Jun	10864051
Pulmonary mucosa-associated lymphoid tissue lymphoma in a patient with common variable immunodeficiency syndrome.	2001	11223743
Bilateral empyema caused by adult-onset Still's disease.	2001	11223737
Cyclophosphamide and antithymocyte globulin to condition patients with aplastic anemia for allogeneic marrow transplantations: the experience in four centers.	2001	11215697
Hodgkin's disease: clinical presentation and treatment.	2001	11191130
The risk of upper gastrointestinal complications associated with nonsteroidal anti-inflammatory drugs, glucocorticoids, acetaminophen, and combinations of these agents.	2001	11178116
Current status of cytotoxic chemotherapy in hormone refractory prostate cancer.	2001 Feb	11223670
Interstitial nephritis in patients with inflammatory bowel disease treated with mesalamine.	2001 Feb	11205659
Circulating CD8+ T cells in polymyalgia rheumatica and giant cell arteritis: a review.	2001 Feb	11182026
Can we induce tolerance in rheumatoid arthritis?	2001 Feb	11177772
Infusional CHOP chemotherapy (CVAD) with or without chemosensitizers offers no advantage over standard CHOP therapy in the treatment of lymphoma: a Southwest Oncology Group Study.	2001 Feb 1	11157027
Long-term results of combined-modality therapy for locally advanced breast cancer with ipsilateral supraclavicular metastases: The University of Texas M.D. Anderson Cancer Center experience.	2001 Feb 1	11157012
Improved response with higher corticosteroid dose in children with acute lymphoblastic leukemia.	2001 Feb 15	11181667
Effect of thymectomy on human peripheral blood T cell pools in myasthenia gravis.	2001 Feb 15	11160348
Survival in patients with intermediate or high grade non-Hodgkin's lymphoma: meta-analysis of randomized studies comparing third generation regimens with CHOP.	2001 Feb 2	11161392
Sample size calculations for the two-sample problem using the multiplicative intensity model.	2001 Feb 28	11223901
Macrohematuria with electron-dense deposits in a 14-year-old boy with minimal change nephrotic syndrome.	2001 Jan	11198614
Fatal cytomegalovirus disease in a high-risk renal transplant recipient.	2001 Jan	11198610
Systemic vasculitis in patients with hepatitis C.	2001 Jan	11196510
Factors associated with low bone mineral density in female patients with systemic lupus erythematosus.	2001 Jan	11196509
A rationale for adjuvant surgical intervention in pyoderma gangrenosum.	2001 Jan	11192029
Effective steroid-sparing treatment for peripheral ulcerative keratitis and pyoderma gangrenosum.	2001 Jan	11188994
Plasmapheresis as an effective treatment for opsoclonus-myoclonus syndrome.	2001 Jan	11182286
Longitudinal assessment of everolimus in de novo renal transplant recipients over the first post-transplant year: pharmacokinetics, exposure-response relationships, and influence on cyclosporine.	2001 Jan	11180038
A high serum-soluble interleukin-2 receptor level is associated with a poor outcome of aggressive non-Hodgkin's lymphoma.	2001 Jan	11168504
Tacrolimus monotherapy in adult cardiac transplant recipients: intermediate-term results.	2001 Jan	11166613
Dose-response analysis for radiotherapy delivered to patients with intermediate-grade and large-cell immunoblastic lymphomas that have completely responded to CHOP-based induction chemotherapy.	2001 Jan 1	11163493
High-dose therapy and autologous bone marrow transplantation for follicular lymphoma in first complete or partial remission: results of a phase II clinical trial.	2001 Jan 15	11154216
Combined treatment of giant-cell arteritis with methotrexate and prednisone. a randomized, double-blind, placebo-controlled trial.	2001 Jan 16	11177313
Ursodiol use is associated with lower prevalence of colonic neoplasia in patients with ulcerative colitis and primary sclerosing cholangitis.	2001 Jan 16	11177311
Autologous hematopoietic stem-cell transplantation for Behçet's disease with pulmonary involvement.	2001 Jan 4	11187123
Retinopathy due to juvenile polymyositis.	2001 Jan-Feb	11201918
Improved outcome for children with acute lymphoblastic leukemia: results of Dana-Farber Consortium Protocol 91-01.	2001 Mar 1	11222362
Comparison of suppressive potency between prednisolone and prednisolone sodium succinate against mitogen-induced blastogenesis of human peripheral blood mononuclear cells in-vitro.	2001 May	11370712
[Acceptability and tolerance of prednisolone metasulfobenzoate in orally dispersing tablets in 2 to 12-years-old children].	2004 Sep	15351007
Clinical trial: oral prednisolone metasulfobenzoate (Predocol) vs. oral prednisolone for active ulcerative colitis.	2008 Feb 1	17988236

Patents

Sample Use Guides

In Vivo Use Guide

Unknown

Route of Administration: Unknown

In Vitro Use Guide

Unknown

Substance Class	Chemical Created by `admin` on `Mon Mar 31 18:11:09 GMT 2025` Edited by `admin` on `Mon Mar 31 18:11:09 GMT 2025`
Record UNII	VB0R961HZT
Record Status	`Validated (UNII)`
Record Version

Download

Name

Type

Language

Prednisone

Official Name

English

PREDNISONE TABLETS

Preferred Name

English

17,21-Dihydroxypregna-1,4-diene-3,11,20-trione

Systematic Name

English

PREGNA-1,4-DIENE-3,11,20-TRIONE, 17,21-DIHYDROXY-

Systematic Name

English

PREDNISONE TABLETS [USP-RS]

Common Name

English

PREDNISONE INTENSOL

Brand Name

English

Prednisone [WHO-DD]

Common Name

English

SUPERCORTIL

Common Name

English

METACORTANDRACIN

Common Name

English

PREDNISONE [USP MONOGRAPH]

Common Name

English

PREDNISONE ANHYDROUS

Common Name

English

3EN3HG4WSW

Common Name

English

PREDNISONE [GREEN BOOK]

Common Name

English

NSC-10023

Code

English

prednisone [INN]

Common Name

English

DELTASONE

Brand Name

English

DEHYDROCORTISONE

Common Name

English

PREDNISONE [USP-RS]

Common Name

English

PREDNISONE [ORANGE BOOK]

Common Name

English

PREDNISONE [EP MONOGRAPH]

Common Name

English

PREDNISONE [IARC]

Common Name

English

PREDNISONE [VANDF]

Common Name

English

PREDNISONE [HSDB]

Common Name

English

PREDNISONE [MART.]

Common Name

English

PREDNISONE [MI]

Common Name

English

DECORTIN

Brand Name

English

PREDNISOLONE IMPURITY B [EP IMPURITY]

Common Name

English

Classification Tree Code System Code

WHO-ATC

H02AB07